

CAPITAL MARKETS DAY 2025





Joakim Skantze
Senior Vice President
Life Science



My journey within Indutrade

Pre Indutrade

- Electrical Engineer, KTH
- Accenture
- Schneider Grafiska AB
- Traction

Indutrade

Industrial Components

- Business Area Manager
 - Net sales: 2.5 BSEK → 6.2 BSEK
 - EBITA margin: 10.6% → 15.9%
 - 19 acquisitions, 45 companies

Life Science


- Business Area Manager
 - Net Sales: 7.4 BSEK 2024
 - EBITA margin: 16.6% 2024
 - 35 companies

1987-2016

2016-2024

2024-

Our Life Science companies



14%	32%	17.8%
Organic growth 5Y avg.	EBITA CAGR -5Y	EBITA margin 5Y avg.
Share of net sales per geographical region		
20%	26%	46%
Sweden	Rest of Nordic	Rest of Europe
Split by company size, Q3-25 YTD		
1	10	24
>500 MSEK	200-500 MSEK	<200 MSEK

Strong position within Pharma production



- Supplier to Pharma manufacturers and CMOs
- Flow related products, assemblies and SU-systems
- High validation and quality driven processes
- Huge market and good underlying growth trend

Examples of trends



Outsourcing



Supply chain
resilience



Regulatory
challenges




Examples Pharma applications

Single Use

Colly FLOWTECH
INNOVATIV FLÖDESTECHNIK



UltraPure International



Flow components

ESI
Technologies Group



Purification skid

Puretech
delivering purity



Niched Medical companies




- Diversified market and multiple segments
- Our position: stronger in the Nordics but many geographical white-spots
- Interesting areas: Diagnostics and Labtech, driven by therapies like cancer treatment, diabetes, health etc.

Examples of trends



Ageing
population



Shortage of
resources



Diagnostics



Examples Medical applications

Diabetes



Medical technology



BEST IQ



Laboratory equipment




Strong and lean international team

- Driven by a strong Purpose
- Enable Business Segments to be engines!
- Professional owner and Partner




"We have the freedom and autonomy to act and develop the BA ourselves, with good support of the Indutrade framework and network."

Leading a Business Area within Indutrade



Developing towards the ideal company



Developing our people



Culture

Indutrade Academy

IBP / ILP / IBCP

Succession planning


Internal vs external

Development plans


Judgement / Drive / Influence



Proactive acquisition agenda



“Driving value creation in a structured way”



Key takeaways



Strong position in pharma
and medical with
significant growth
potential



Full responsibility for
developing our
companies and value-
accretive **acquisitions**



Lean international team
driven by a **strong**
purpose

Full autonomy but benefitting from the Indutrade infrastructure

